Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Giovanni Martinelli, Caterina De Benedittis et al.|Cancer|2013Cited by 143
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term OutcomeFederico Lussana, Alessandro Rambaldi, Ernesta Audisio et al.|Transplantation and Cellular Therapy|2016Cited by 88
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemiaRenato Bassan, Alessandro Rambaldi, Orietta Spinelli et al.|Blood Cancer Journal|2014Cited by 63
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphomaNicola Gökbuget, D. Hoelzer, Christine-Maria Hartog et al.|Haematologica|2010Cited by 63
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07Renato Bassan, Alessandro Rambaldi, Chiara Pavoni et al.|Blood Cancer Journal|2020Cited by 45